

Table S1 Clinicopathological characteristics of the 21 patients with LNR

Patient	Risk group	Risk factors	Sites of recurrence	RFS (months)	Number of LNs removed	Range of lymphadenectomy
01	High-intermediate	≥65 years old; stage II; G3; ≥2 cm	Left iliac LNs	20	38	PPALND
02	High	≥65 years old; stage IIIC2; clear cell; LVSI; ≥2 cm; CA125 ≥35 U/mL	Retroperitoneal LNs	7	20	PPALND
03	High	≥65 years old; stage IIIB; CNH; serous; ≥2 cm; MI ≥1/2	Para-aortic LNs	5	22	PPALND
04	Low	None	Perirenal LNs	25	31	PPALND
05	High	Stage IIIC1; LVSI	Retroperitoneal LNs, bilateral inguinal LNs	39	23	PLND
06	High	Stage IIIC2; serous; LVSI; ≥2 cm; MI ≥1/2; CSI	Para-aortic LNs, pulmonary LNs	8	19	PPALND
07	High	Stage IIIC1; G3	Pelvic LNs, retroperitoneal LNs, left supraclavicular LNs	18	33	PPALND
08	High	≥65 years old; serous; ≥2 cm	Mediastinal and bilateral hilar LNs, right iliac LNs, para-aortic LNs	35	26	PPALND
09	High	Stage IIIA; cytology (+); ≥2 cm; CA125 ≥35 U/mL	Cardio-diaphragmatic angle LNs, hepatic hilar LNs; abdominal cavity (soft tissue mass between diaphragm and liver); liver	22	20	PLND
10	High	≥65 years old; stage IIIC1; G3; ≥2 cm, CA125 ≥35 U/mL, MI ≥1/2	Left inguinal LNs; vaginal cuff; lung	35	19	PLND
11	Metastatic	Stage IVB; G3; cytology (+); ≥2 cm; CA125 ≥35 U/mL; MI ≥1/2; LNM	Right iliac LNs; vaginal cuff	11	56	PPALND
12	Metastatic	Stage IVB; serous; LVSI; cytology (+); ≥2 cm, CA125 ≥35 U/mL; LNM; adnexal involvement	Intraperitoneal LNs; lung	6	51	PPALND
13	Metastatic	≥65 years old; stage IVB; serous; ≥2 cm; CA125 ≥35 U/mL; adnexal involvement	Bilateral iliac LNs; Mesenteric LNs, intraperitoneal LNs; vaginal cuff; peritoneal cytology (+)	11	0	None
14	Intermediate	Stage IB; ≥2 cm; CA125 ≥35 U/mL	Cervical LNs, axillary LNs; breast skin, lung, ilium, liver; mediastinal	14	6	PLND
15	Low	≥2 cm	Left iliac LNs; right ischium	22	18	PPALND
16	Intermediate	≥65 years old; G3; ≥2 cm	Retroperitoneum LNs, intraperitoneal LNs; peritoneal cavity, great omentum	38	0	None
17	High-intermediate	Stage IB; G3	Right iliac LNs; peritoneal cavity; lungs	4	17	PLND
18	Metastatic	Stage IVB; G3; ≥2 cm	Left inguinal LNs; pelvic cavity; peritoneal cavity	16	0	None
19	High	Stage IIIC2; clear cell; LVSI; ≥2 cm	Bilateral iliac and retroperitoneal LNs, bilateral inguinal LNs, mediastinal LNs; vaginal cuff, pelvic cavity; hilar area; lungs	7	24	PPALND
20	Metastatic	Stage IVB; serous; LVSI; cytology (+); ≥2 cm; CA125 ≥35 U/mL; MI ≥1/2; adnexal involvement; LNM	Pelvic and intraperitoneal LNs; pelvic intestinal space; peritoneum	14	15	PPALND
21	Metastatic	Stage IVB; LVSI; cytology (+); ≥2 cm; MI ≥1/2; adnexal involvement; LNM	Para-pancreatic LNs, right supraclavicular LNs, bilateral mandibular LNs; vaginal cuff; liver	24	19	PPALND

LVSI, lymphovascular space invasion; CA125, carbohydrate antigen 125; CNH, copy-number high; MI, myometrial invasion; CSI, cervical stroma invasion; LNM, lymph node metastasis; LNs, lymph nodes; RFS, recurrence-free survival; PPALND, pelvic and para-aortic lymphadenectomy; PLND, pelvic lymphadenectomy.




Figure S1 Multiple patterns of recurrence of LNR. LN, lymph node; LNR, lymph node recurrence.